Literature DB >> 19793806

Identification of B-cell epitopes on virus-like particles of cutaneous alpha-human papillomaviruses.

Tilo Senger1, Maria R Becker, Lysann Schädlich, Tim Waterboer, Lutz Gissmann.   

Abstract

Human papillomavirus (PV) (HPV) types 2, 27, and 57 are closely related and, hence, represent a promising model system to study the correlation of phylogenetic relationship and immunological distinctiveness of PVs. These HPV types cause a large fraction of cutaneous warts occurring in immunocompromised patients. Therefore, they constitute a target for the development of virus-like particle (VLP)-based vaccines. However, the immunogenic structure of HPV type 2, 27, and 57 capsids has not been studied yet. Here we provide, for the first time, a characterization of the B-cell epitopes on VLPs of cutaneous alpha-HPVs using a panel of 94 monoclonal antibodies (MAbs) generated upon immunization with capsids from HPV types 2, 27, and 57. The MAbs generated were characterized regarding their reactivities with glutathione S-transferase-L1 fusion proteins from 18 different PV types, the nature of their recognized epitopes, their isotypes, and their ability to neutralize HPV type 2, 27, 57, or 16. In total, 33 of the 94 MAbs (35%) showed type-specific reactivity. All type-specific MAbs recognize linear epitopes, most of which map to the hypervariable surface loop regions of the L1 amino acid sequence. Four of the generated MAbs neutralized pseudovirions of the inoculated HPV type efficiently. All four MAbs recognized epitopes within the BC loop, which is required and sufficient for their neutralizing activity. Our data highlight the immunological distinctiveness of individual HPV types, even in comparison to their closest relatives, and they provide a basis for the development of VLP-based vaccines against cutaneous alpha-HPVs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19793806      PMCID: PMC2786864          DOI: 10.1128/JVI.01582-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  58 in total

1.  Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope.

Authors:  R B Roden; A Armstrong; P Haderer; N D Christensen; N L Hubbert; D R Lowy; J T Schiller; R Kirnbauer
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

2.  Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types.

Authors:  Raeda Z Rizk; Neil D Christensen; Kristina M Michael; Martin Müller; Peter Sehr; Tim Waterboer; Michael Pawlita
Journal:  J Gen Virol       Date:  2008-01       Impact factor: 3.891

3.  Chimeric papillomavirus-like particles.

Authors:  M Müller; J Zhou; T D Reed; C Rittmüller; A Burger; J Gabelsberger; J Braspenning; L Gissmann
Journal:  Virology       Date:  1997-07-21       Impact factor: 3.616

4.  Interlaboratory agreement among results of human papillomavirus type 16 enzyme-linked immunosorbent assays.

Authors:  H D Strickler; A Hildesheim; R P Viscidi; K V Shah; B Goebel; J Drummond; D Waters; Y Sun; N L Hubbert; S Wacholder; L A Brinton; C L Han; P C Nasca; R McClimens; K Turk; V Devairakkam; S Leitman; C Martin; J T Schiller
Journal:  J Clin Microbiol       Date:  1997-07       Impact factor: 5.948

5.  Two amino acid residues confer type specificity to a neutralizing, conformationally dependent epitope on human papillomavirus type 11.

Authors:  S W Ludmerer; D Benincasa; G E Mark
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

6.  Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies.

Authors:  N D Christensen; J Dillner; C Eklund; J J Carter; G C Wipf; C A Reed; N M Cladel; D A Galloway
Journal:  Virology       Date:  1996-09-01       Impact factor: 3.616

7.  A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response.

Authors:  Nadja Thönes; Anna Herreiner; Lysann Schädlich; Konrad Piuko; Martin Müller
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

8.  A prospective pilot study of antibodies against human papillomaviruses and cutaneous squamous cell carcinoma nested in the Oxford component of the European Prospective Investigation into Cancer and Nutrition.

Authors:  Delphine Casabonne; Kristina M Michael; Tim Waterboer; Michael Pawlita; Ola Forslund; Robert D Burk; Ruth C Travis; Tim J Key; Robert Newton
Journal:  Int J Cancer       Date:  2007-10-15       Impact factor: 7.396

9.  A neutralizing epitope of human papillomavirus type 11 is principally described by a continuous set of residues which overlap a distinct linear, surface-exposed epitope.

Authors:  S W Ludmerer; D Benincasa; G E Mark; N D Christensen
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

10.  Production of papillomavirus-based gene transfer vectors.

Authors:  Christopher B Buck; Cynthia D Thompson
Journal:  Curr Protoc Cell Biol       Date:  2007-12
View more
  10 in total

1.  Evaluation of a novel multiplex human papillomavirus (HPV) genotyping assay for HPV types in skin warts.

Authors:  Markus Schmitt; Maurits N C de Koning; Just A H Eekhof; Wim G V Quint; Michael Pawlita
Journal:  J Clin Microbiol       Date:  2011-08-03       Impact factor: 5.948

2.  Characterization of monoclonal antibodies specific for the Merkel cell polyomavirus capsid.

Authors:  Diana V Pastrana; Katherine A Pumphrey; Nicolas Cuburu; Rachel M Schowalter; Christopher B Buck
Journal:  Virology       Date:  2010-07-03       Impact factor: 3.616

3.  Virus-like particles and capsomeres are potent vaccines against cutaneous alpha HPVs.

Authors:  Tilo Senger; Lysann Schädlich; Sonja Textor; Corinna Klein; Kristina M Michael; Christopher B Buck; Lutz Gissmann
Journal:  Vaccine       Date:  2009-12-08       Impact factor: 3.641

4.  Identification and localization of minimal MHC-restricted CD8+ T cell epitopes within the Plasmodium falciparum AMA1 protein.

Authors:  Martha Sedegah; Yohan Kim; Bjoern Peters; Shannon McGrath; Harini Ganeshan; Jennylynn Lejano; Esteban Abot; Glenna Banania; Maria Belmonte; Renato Sayo; Fouzia Farooq; Denise L Doolan; David Regis; Cindy Tamminga; Ilin Chuang; Joseph T Bruder; C Richter King; Christian F Ockenhouse; Bart Faber; Edmond Remarque; Michael R Hollingdale; Thomas L Richie; Alessandro Sette
Journal:  Malar J       Date:  2010-08-24       Impact factor: 2.979

5.  Prediction of B-cell linear epitopes with a combination of support vector machine classification and amino acid propensity identification.

Authors:  Hsin-Wei Wang; Ya-Chi Lin; Tun-Wen Pai; Hao-Teng Chang
Journal:  J Biomed Biotechnol       Date:  2011-08-23

6.  Determination of Causative Human Papillomavirus Type in Tissue Specimens of Common Warts Based on Estimated Viral Loads.

Authors:  Vesna Breznik; Kristina Fujs Komloš; Lea Hošnjak; Boštjan Luzar; Rajko Kavalar; Jovan Miljković; Mario Poljak
Journal:  Front Cell Infect Microbiol       Date:  2020-01-24       Impact factor: 5.293

7.  Next generation L2-based HPV vaccines cross-protect against cutaneous papillomavirus infection and tumor development.

Authors:  Melinda Ahmels; Filipe C Mariz; Ilona Braspenning-Wesch; Sonja Stephan; Bettina Huber; Gabriele Schmidt; Rui Cao; Martin Müller; Reinhard Kirnbauer; Frank Rösl; Daniel Hasche
Journal:  Front Immunol       Date:  2022-10-03       Impact factor: 8.786

8.  Multivalent human papillomavirus l1 DNA vaccination utilizing electroporation.

Authors:  Kihyuck Kwak; Rosie Jiang; Subhashini Jagu; Joshua W Wang; Chenguang Wang; Neil D Christensen; Richard B S Roden
Journal:  PLoS One       Date:  2013-03-25       Impact factor: 3.240

9.  Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses.

Authors:  Christina Schellenbacher; Kihyuck Kwak; Dieter Fink; Saeed Shafti-Keramat; Bettina Huber; Christoph Jindra; Helena Faust; Joakim Dillner; Richard B S Roden; Reinhard Kirnbauer
Journal:  J Invest Dermatol       Date:  2013-05-10       Impact factor: 8.551

10.  Expression of different L1 isoforms of Mastomys natalensis papillomavirus as mechanism to circumvent adaptive immunity.

Authors:  Sabrina E Vinzón; Frank Rösl; Daniel Hasche; Yingying Fu; Rui Cao; Miriam Schäfer; Sonja Stephan; Ilona Braspenning-Wesch; Laura Schmitt; Ralf Bischoff; Martin Müller; Kai Schäfer
Journal:  Elife       Date:  2020-08-04       Impact factor: 8.140

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.